The DNA Medicine Institute, Inc.

The DNA Medicine Institute, Inc., based in Bedford, Massachusetts, is a for-profit Subchapter S corporation and small business that delivers advanced medical diagnostic and point-of-care testing devices to federal agencies as a prime contractor, with no subcontractor footprint across its federal award portfolio. The vendor operates entirely on full-and-open competition with no set-aside designations, competing across NASA, the National Institutes of Health, the Department of Health and Human Services, and the Department of Defense on research, development, and prototype delivery contracts for optical cytometry systems, microfluidic diagnostic cartridges, and space-flight medical instrumentation.

DNA Medicine Institute's recent customer concentration centers on NASA internal research centers. The National Aeronautics and Space Administration Shared Services Center and Glenn Research Center together account for 50% of awards and $5.5 million of combined potential value; the National Heart Lung and Blood Institute holds three awards; and the Johnson Space Center adds two awards worth $850 thousand. The Missile Defense Agency represents the vendor's newest entry point, with a position on the Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) multiple-award IDIQ—a $151 billion defense procurement vehicle issued December 29, 2025, with an initial delivery order ceiling of $500 for unclassified and classified systems engineering, research and development, prototyping, and weapon design across air, missile, space, cyber, and hybrid threats. The vendor also holds a GSA Multiple Award Schedule contract effective through June 17, 2030, with a $2 million ceiling, covering engineering research and development services and strategic planning under Special Item Numbers 541715 (Engineering Research and Development and Strategic Planning) and OLM (Order Level Materials).

Representative work includes a $741,584 Firm Fixed Price definitive contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (award date September 26, 2022, completion October 18, 2024) to design and build a low-cost, disposable flow cell adapting the vendor's existing space-flight optical cytometry module into an accessible point-of-care optical solution. A Phase II Direct-to-Phase II grant from the National Heart Lung and Blood Institute (awarded September 10, 2024, completion August 31, 2026) funds development of a multiplexed 5-minute point-of-care anti-Factor Xa and hemoglobin test for emergent management of bleeding and stroke in patients on direct oral anticoagulants, leveraging proprietary CE-marked substrate and rHealth point-of-care device technology. NASA contracts span optical cytometry systems, space-flight hardware qualification, and advanced medical instrumentation prototyping.

Award activity has been sporadic but recently accelerated: one award in 2018, one in 2020, one in 2022, one in 2024, and three awards in 2025. Combined potential value sits at $9.1 million across eighteen prime awards; however, combined obligated dollars ($19.4 million) exceed potential value, indicating prior-year task order funding against NASA and HHS contracts. Two awards reach ultimate completion within the next twenty-four months, exposing minimal recompete cliff exposure. The vendor's NAICS concentration runs across research and development in physical, engineering, and life sciences (ten awards) and research and development in biotechnology (three awards), with PSC coding dominated by space R&D services and supporting activities (eight awards). On its GSA Schedule position, DNA Medicine Institute maintains six labor categories spanning engineering technicians ($93.42/hr) through principal engineers and scientists with doctorate education ($224.83/hr), with no security-cleared positions. SCI-reported invoicing captured only a single contract in FY2024 at $742 thousand across 357 FTEs, yielding a nominal $1.00/hr blended rate—a data artifact of how the underlying contract-hour allocation was reported rather than actual compensation posture—so the GSA Schedule rate bands ($93–$225/hr) better reflect the vendor's actual labor pricing. The vendor operates a pure-prime model with zero subcontractor engagement.

Nanotechnology, genomics, bioengineering, research